Filing Details

Accession Number:
0001209191-11-021309
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-04-04 20:29:04
Reporting Period:
2011-03-31
Filing Date:
2011-04-04
Accepted Time:
2011-04-04 20:29:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012140 Onyx Pharmaceuticals Inc ONXX Biological Products, (No Disgnostic Substances) (2836) 943154463
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1282660 R Julianna Wood C/O Onyx Pharmaceuticals, Inc.
249 East Grand Ave.
South San Francisco CA 94080
Vp, Public Affairs No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-03-31 2,500 $0.00 10,953 No 4 A Direct
Common Stock Acquisiton 2011-03-31 8,000 $0.00 118,953 No 4 A Direct
Common Stock Disposition 2011-03-31 428 $35.18 18,525 No 4 F Direct
Common Stock Disposition 2011-04-01 1,078 $35.02 17,447 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2011-03-31 17,500 $0.00 17,500 $35.18
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
17,500 2021-03-31 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 200 Indirect Childrens' Trust
Footnotes
  1. Represents a restricted stock award granted to the reporting person. The restricted stock award vests annually over 3 years.
  2. Represents restricted stock units granted to the reporting person. Each restricted stock unit represents a right to receive one share of the issuer's common stock. The restricted stock unit vests upon the meeting of certain milestones.
  3. Payment of exercise price or tax liability by delivering or withholding securities incident to receipt, exercise or vesting of a security issued in accordance with Rule 16b-3.
  4. Shares sold pursuant to a 10b5-1 plan.
  5. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.